# Sofosbuvir-Velpatasvir

## Epclusa 400/100mg

| 藥物代碼 | OEPC |
| :--- | :--- |
| 適應症 | treatment of adult chronic hepatitis C virus \(HCV\) genotype 1, 2, 3, 4, 5 or 6 infections |
| 副作用 | &gt;10%: Central nervous system: Headache \(22%\), fatigue \(15%\)1% to 10%:Central nervous system: Irritability \(?5%\), insomnia \(5%\), depression \(1%\)Dermatologic: Skin rash \(2%\)Gastrointestinal: Nausea \(9%\), increased serum lipase \(&gt;3X ULN: 3% to 6%\)Neuromuscular & skeletal: Weakness \(5%\), increased creatine phosphokinase \(?10X ULN: 1% to 2%\)Frequency not defined: Infection: Reactivation of HBV&lt;1%: postmarketing, and/or case reports: Angioedema |
| 禁忌 | Hypersensitivity to sofosbuvir, velpatasvir, or any component of the formulation. If sofosbuvir/velpatasvir is administered with ribavirin, the contraindications to ribavirin also apply. See ribavirin manufacturer's labeling information. |
| 藥物保存方式 | 室溫 |
| 用法用量 | The recommended dose for Epclusa is to take a tablet with or without food once a day. When used in combination with EPCLUSA, the recommended dose of ribavirin is based on body weight \(consistent with food\): 1000 mg per day for patients weighing &lt; 75 kg and 1200 mg for weight &gt;= 75 kg, and should be divided into twice daily doses. . The initial dose of Ribavirin and the dose during treatment can be adjusted according to the hemoglobin and creatinine clearance rates. For the dosage adjustment method of ribavirin, please refer to the prescription information containing ribavirin. |
| 肝功能異常 | 無需調整劑量  對輕度、中度或重度肝功能不全（CPT A、B或C級）的患者，並不須調整Epclusa的劑量。曾針對併有CPT B級肝硬化的患者評估過Epclusa的安全性與療效，但尚未對併有CPT C級肝硬化的患者進行過這方面的評估 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | Sofosbuvir: No Human Data—Animal Data Suggest Low Risk \(Contraindicated if combined with Ribavirin\) Velpatasvir: UNKNOW |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | Sofosbuvir: No Human Data—Probable Compatible \(Potential toxicity if combined with Ribavirin\) Velpatasvir: UNKNOW |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

